Helixgate

Helixgate

Uncategorized

Convert nonresponder insights into smarter drug development strategies in immunology

Published

on

While agents like AbbVie’s Humira have transformed the treatment landscape, not all patients benefit equally from the drug. Better biomarker analysis and more investment in mechanistic trials can inform the development of more effective therapies with broader clinical value.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

On the chopping block? When layoffs may and may not lurk around the corner

Published

on

Cost cutting is just one factor driving biopharmas to whittle away at their workforces. An analyst discusses more common reasons layoffs occur and which employees are most at risk.

Continue Reading

Uncategorized

Ones to watch: 4 biotechs with recent Series B raises (that are also hiring)

Published

on

Biopharmas that announced Series B financing this year and are looking for employees as they grow include two companies that received $100 million or more. One has partnerships with three Big Pharmas.

Continue Reading

Uncategorized

Kardigan extends biotech’s streak of big IPOs with $400M haul

Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.

Read More

Published

on

Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.

Read More

Continue Reading
Advertisement

Trending